Discover our KEYconversations meeting highlights

Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) [External links]

MDT KEYconversations in Renal Cell Carcinoma:

Collaboration to optimise patient care and pathways

Meeting held on Wednesday 6^th March 2024

This is a summary report of a promotional meeting organised and funded by MSD for UK healthcare professionals only. MSD products were discussed at the meeting.

About the meeting

On Wednesday 6^th March, over 100 MDT members from across the UK gathered to discuss the evolving treatment landscape for patients diagnosed with RCC.

The meeting was led by an expert panel and chaired by Dr Ricky Frazer (Consultant Medical Oncologist, Velindre Cancer Centre). There were many insightful discussions around key topics, including addressing patient unmet needs and fears, when and how to start the adjuvant treatment conversation, and the identification and management of immune-mediated AEs.

Meeting objectives:

To explore how advances in RCC care, from surgery to systemic treatment, impact patient outcomes
To discuss when and how RCC patients are informed of their treatment options
To share real-world case studies and address AE management associated with MSD’s licensed treatments in the adjuvant and advanced setting
To foster an interactive environment that drives knowledge exchange and collaboration across the full MDT

Click below to find out more about:

Full agenda

Expert panel

Session summaries

Attendee highlights

Attendee feedback shared on the day:

“The exchange of knowledge and feedback was dynamic and informative”

“Key theme throughout the day was the importance of communication and all aspects of the patient journey”

For more information about this meeting or any other topics relating to RCC, email us at: msdukoncology@msd.com

Keep updated on insightful future events by signing up here

This link will take you to an MSD website to give your consent to receive marketing and promotional emails from MSD about our products, services and events.

KEYTRUDA® (pembrolizumab) indications:

KEYTRUDA as monotherapy is indicated for the adjuvant treatment of adults with renal cell carcinoma at increased risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions¹
KEYTRUDA, in combination with lenvatinib, is indicated for the first-line treatment of advanced renal cell carcinoma in adults¹
KEYTRUDA, in combination with axitinib, is indicated for the first-line treatment of advanced renal cell carcinoma in adults¹

MSD does not recommend the use of products outside of their licensed indications. Please refer to the Summary of Product Characteristics (and Risk Minimisation Materials) available on the EMC website before prescribing.

Abbreviations

AE, adverse event; MDT, multidisciplinary team; RCC, renal cell carcinoma.

Reference

KEYTRUDA Summary of Product Characteristics.

Supporting documentation

Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland)
By clicking the links above you will leave the MSD Connect website and be taken to the emc PI portal website